SG11201906671SA - Compositions and methods for inhibiting reticulon 4 - Google Patents
Compositions and methods for inhibiting reticulon 4Info
- Publication number
- SG11201906671SA SG11201906671SA SG11201906671SA SG11201906671SA SG11201906671SA SG 11201906671S A SG11201906671S A SG 11201906671SA SG 11201906671S A SG11201906671S A SG 11201906671SA SG 11201906671S A SG11201906671S A SG 11201906671SA SG 11201906671S A SG11201906671S A SG 11201906671SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- co7c
- compositions
- methods
- oakland
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/27—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/09—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 09 August 2018 (09.08.2018) WI P0 I P C T olimion °nolo DID Ho mil 01O 1110110111110 oimIE (10) International Publication Number WO 2018/144870 Al (51) International Patent Classification: A61K 31/275 (2006.01) CO7C 255/23 (2006.01) A61K 31/277 (2006.01) CO7C 255/31 (2006.01) A61P 35/00 (2006.01) CO7C 317/32 (2006.01) (21) International Application Number: PCT/US2018/016650 (22) International Filing Date: 02 February 2018 (02.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/454,681 03 February 2017 (03.02.2017) US 62/471,865 15 March 2017 (15.03.2017) US (71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street, Twelfth Floor, Oakland, CA 94607-5200 (US). (72) Inventors: NOMURA, Daniel, K.; 4532 Davenport Av- enue, Berkeley, CA 94619 (US). OLZMANN, James, A.; 2269 Mastlands Drive, Oakland, CA 94611 (US). BATE- MAN, Leslie, A.; 51 Hancock Street, #12B, Boston, MD 02114 (US). NGUYEN, Truc, B.; 660 Kinkead Way, Apt. 201, Albany, CA 94706 (US). MIYAMOTO, David, K.; 380 Green St., Cambridge, MA 02139 (US). HUFFMAN, Tucker, R.; 1821 Sapphire Way, El Dorado Hills, CA 95762 (US). ROBERTS, Allison, M.; 523 Coventry Rd, Kensington, CA 94707 (US). (74) Agent: TERRANOVA, Zachary, L. et al.; Mintz Levin Cohn Ferris Glovsky Popeo, P.C., One Financial Center, Boston, MA 02111 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 FIG. 1D 8W620 cell pathogen survival proliferation (57) : Disclosed herein, inter alia, are compositions and methods useful for inhibiting reticulon 4(RTN4). [Continued on next page] C WO 2018/144870 Al MIDEDIMOMMIDIREEMOMOEMOIFICIMMOVOIMIE Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762454681P | 2017-02-03 | 2017-02-03 | |
US201762471865P | 2017-03-15 | 2017-03-15 | |
PCT/US2018/016650 WO2018144870A1 (en) | 2017-02-03 | 2018-02-02 | Compositions and methods for inhibiting reticulon 4 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201906671SA true SG11201906671SA (en) | 2019-08-27 |
Family
ID=63040209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201906671SA SG11201906671SA (en) | 2017-02-03 | 2018-02-02 | Compositions and methods for inhibiting reticulon 4 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20200062696A1 (en) |
EP (1) | EP3576728A4 (en) |
JP (1) | JP2020506935A (en) |
KR (1) | KR20190126074A (en) |
CN (1) | CN110461322A (en) |
AU (1) | AU2018215447A1 (en) |
BR (1) | BR112019016132A2 (en) |
CA (1) | CA3051587A1 (en) |
MX (1) | MX2019009200A (en) |
SG (1) | SG11201906671SA (en) |
WO (1) | WO2018144870A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3841091A1 (en) * | 2018-08-24 | 2021-06-30 | Xeniopro GmbH | Phenoxy(hetero)aryl ethers of antiproliferative activity |
BR112022012471A2 (en) * | 2019-12-24 | 2022-11-29 | Dana Farber Cancer Inst Inc | ENHANCED ASSOCIATED TRANSCRIPTIONAL DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL102790A (en) * | 1991-09-17 | 1996-01-31 | Roussel Uclaf | 3-Cycloalkyl-prop-2- enamide derivatives |
US5922775A (en) * | 1997-10-23 | 1999-07-13 | Octamer, Inc. | Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity |
US7928127B2 (en) * | 2005-05-19 | 2011-04-19 | Notre Dame University | Inhibitors of matrix metallaproteinases |
WO2012004773A1 (en) * | 2010-07-09 | 2012-01-12 | Universite De Geneve | New uses of nogo-a inhibitors and related methods |
WO2012164103A2 (en) * | 2011-06-03 | 2012-12-06 | Universität Zürich | Blockers of the nogo-a s1pr pathway for the treatment of diseases characterized by neuronal damage and lack of subsequent repair |
ES2762193T3 (en) * | 2011-08-03 | 2020-05-22 | Univ Nat Taiwan | Protein tyrosine phosphatase 1 agonists containing Src-2 homology domain and treatment methods using the same |
WO2013152135A1 (en) * | 2012-04-04 | 2013-10-10 | Dawei Zhang | Substituted quinolines as bruton's tyrosine kinases inhibitors |
EP3033625B1 (en) * | 2013-08-13 | 2020-01-22 | The Scripps Research Institute | Cysteine-reactive ligand discovery in proteomes |
JP6513076B2 (en) * | 2014-02-28 | 2019-05-15 | 国立大学法人東北大学 | Amide derivatives |
WO2015160307A1 (en) * | 2014-04-16 | 2015-10-22 | Nanyang Technological University | Allenamide as an orthogonal handle for selective modification of cysteine in peptides and proteins |
KR20170103838A (en) * | 2015-01-23 | 2017-09-13 | 컨플루언스 라이프 사이언시스, 인코포레이티드 | Heterocyclic itk inhibitors for treating inflammation and cancer |
EP3365686A4 (en) * | 2015-10-22 | 2019-03-27 | The Scripps Research Institute | Cysteine reactive probes and uses thereof |
-
2018
- 2018-02-02 AU AU2018215447A patent/AU2018215447A1/en not_active Abandoned
- 2018-02-02 US US16/482,947 patent/US20200062696A1/en not_active Abandoned
- 2018-02-02 EP EP18747169.3A patent/EP3576728A4/en not_active Withdrawn
- 2018-02-02 MX MX2019009200A patent/MX2019009200A/en unknown
- 2018-02-02 KR KR1020197025643A patent/KR20190126074A/en unknown
- 2018-02-02 CN CN201880020332.2A patent/CN110461322A/en active Pending
- 2018-02-02 CA CA3051587A patent/CA3051587A1/en not_active Abandoned
- 2018-02-02 WO PCT/US2018/016650 patent/WO2018144870A1/en unknown
- 2018-02-02 BR BR112019016132A patent/BR112019016132A2/en not_active Application Discontinuation
- 2018-02-02 SG SG11201906671SA patent/SG11201906671SA/en unknown
- 2018-02-02 JP JP2019542113A patent/JP2020506935A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200062696A1 (en) | 2020-02-27 |
MX2019009200A (en) | 2019-10-21 |
WO2018144870A1 (en) | 2018-08-09 |
KR20190126074A (en) | 2019-11-08 |
CN110461322A (en) | 2019-11-15 |
EP3576728A1 (en) | 2019-12-11 |
AU2018215447A1 (en) | 2019-08-08 |
CA3051587A1 (en) | 2018-08-09 |
BR112019016132A2 (en) | 2020-04-07 |
EP3576728A4 (en) | 2020-08-12 |
WO2018144870A8 (en) | 2019-09-06 |
JP2020506935A (en) | 2020-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201906395PA (en) | Blockchain based data processing method and device | |
SG11201900596XA (en) | Cannabis composition | |
SG11201900501RA (en) | Cannabis composition | |
SG11201804041QA (en) | High conductivity graphane-metal composite and methods of manufacture | |
SG11201902857SA (en) | Activatable anti-ctla-4 antibodies and uses thereof | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201903359RA (en) | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma | |
SG11202000131VA (en) | Substituted aluminum nitride for improved acoustic wave filters | |
SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
SG11201807252QA (en) | Anti-lag-3 antibodies | |
SG11201805449PA (en) | Methods of making chimeric antigen receptor -expressing cells | |
SG11201806745RA (en) | Sulfonylureas and related compounds and use of same | |
SG11201907857RA (en) | Edible and biodegradable utensils | |
SG11201805493YA (en) | Binding members with altered diversity scaffold domains | |
SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
SG11201908560SA (en) | Heterocyclic compounds useful as dual atx/ca inhibitors | |
SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
SG11201807770RA (en) | Sequence arrangements and sequences for neoepitope presentation | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
SG11201900665VA (en) | Cannabis composition |